» Articles » PMID: 23374706

Tumor Vasculature Targeting and Imaging in Living Mice with Reduced Graphene Oxide

Overview
Journal Biomaterials
Date 2013 Feb 5
PMID 23374706
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Graphene-based nanomaterials have attracted tremendous attention in the field of biomedicine due to their intriguing properties. Herein, we report tumor vasculature targeting and imaging in living mice using reduced graphene oxide (RGO), which was conjugated to the anti-CD105 antibody TRC105. The RGO conjugate, (64)Cu-NOTA-RGO-TRC105, exhibited excellent stability in vitro and in vivo. Serial positron emission tomography (PET) imaging studies non-invasively assessed the pharmacokinetics and demonstrated specific targeting of (64)Cu-NOTA-RGO-TRC105 to 4T1 murine breast tumors in vivo, compared to non-targeted RGO conjugate ((64)Cu-NOTA-RGO). In vivo (e.g., blocking 4T1 tumor uptake with excess TRC105), in vitro (e.g., flow cytometry), and ex vivo (e.g., histology) experiments confirmed the specificity of (64)Cu-NOTA-RGO-TRC105 for tumor vascular CD105. Since RGO exhibits desirable properties for photothermal therapy, the tumor-specific RGO conjugate developed in this work may serve as a promising theranostic agent that integrates imaging and therapeutic components.

Citing Articles

Paclitaxel-Loaded, Pegylated Carboxylic Graphene Oxide with High Colloidal Stability, Sustained, pH-Responsive Release and Strong Anticancer Effects on Lung Cancer A549 Cell Line.

Angelopoulou A, Papachristodoulou M, Voulgari E, Mouikis A, Zygouri P, Gournis D Pharmaceutics. 2024; 16(11).

PMID: 39598575 PMC: 11597291. DOI: 10.3390/pharmaceutics16111452.


Graphene and its hybrid nanocomposite: A Metamorphoses elevation in the field of tissue engineering.

Singh R, Rawat H, Kumar A, Gandhi Y, Kumar V, Mishra S Heliyon. 2024; 10(13):e33542.

PMID: 39040352 PMC: 11261797. DOI: 10.1016/j.heliyon.2024.e33542.


Shedding light on the use of graphene oxide-thiosemicarbazone hybrids towards the rapid immobilisation of methylene blue and functional coumarins.

Bradley D, Sarpaki S, Mirabello V, Giuffrida S, Kociok-Kohn G, Calatayud D Nanoscale Adv. 2024; 6(9):2287-2305.

PMID: 38694476 PMC: 11059481. DOI: 10.1039/d3na01042b.


Application Research Progress of Nanomaterial Graphene and its Derivative Complexes in Tumor Diagnosis and Therapy.

Cui L, Fan L, Shen Z Curr Med Chem. 2024; 31(39):6436-6459.

PMID: 38299292 DOI: 10.2174/0109298673251648231106112354.


Theranostic Applications of 2D Graphene-Based Materials for Solid Tumors Treatment.

Iannazzo D, Celesti C, Giofre S, Ettari R, Bitto A Nanomaterials (Basel). 2023; 13(16).

PMID: 37630966 PMC: 10459055. DOI: 10.3390/nano13162380.


References
1.
Service R . Materials science. Carbon sheets an atom thick give rise to graphene dreams. Science. 2009; 324(5929):875-7. DOI: 10.1126/science.324_875. View

2.
Robinson J, Tabakman S, Liang Y, Wang H, Sanchez Casalongue H, Vinh D . Ultrasmall reduced graphene oxide with high near-infrared absorbance for photothermal therapy. J Am Chem Soc. 2011; 133(17):6825-31. DOI: 10.1021/ja2010175. View

3.
Feng L, Liu Z . Graphene in biomedicine: opportunities and challenges. Nanomedicine (Lond). 2011; 6(2):317-24. DOI: 10.2217/nnm.10.158. View

4.
Davis M, Chen Z, Shin D . Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7(9):771-82. DOI: 10.1038/nrd2614. View

5.
Liu Z, Cai W, He L, Nakayama N, Chen K, Sun X . In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol. 2008; 2(1):47-52. DOI: 10.1038/nnano.2006.170. View